药物详细合成路线
| Name | Deforolimus;AP-23573 | | Chemical Name | (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-12-[(1R)-2-[(1S,3R,4R)-4-[(Dimethylphosphinoyl)oxy]-3-methoxycyclohexyl]-1-methylethyl]-1,18-dihydroxy-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraene- 2,3,10,14,20-pentone
Dimethylphosphinic acid rapamycin-40-O-yl ester | | CAS | 572924-54-0 | | Related CAS | | | Formula | C53H84NO14P | | Structure |  | | Formula Weight | 990.2062 | | Stage | II 期临床 | | Company | Ariad Pharmaceuticals, Inc. (US); licensed to Merck & Co. for co-development and co-marketing. | | Activity/Mechanism | mTor inhibitor, Oncolytic | | Syn. Route | 1 |
来源:药化网
作者:药化小编
摘要:本文合成路线介绍的是药物中文名Deforolimus；英文名Deforolimus;AP-23573；CAS[572924-54-0]
|
